Compare Davita Inc (DVA) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares Global Tech ETF — how do they compare? Davita Inc trades at $227.08 (market cap $14.92B), while iShares Global Tech ETF trades at $138.19. The key difference: Davita Inc is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| DVA | IXN | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Sector/Thematic |
52-Week High | $235.71 | $149.74 |
52-Week Low | $103.87 | $94.04 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
IXN trades at $136.67, down 2.88% over the past day, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers concentrated exposure to global technology leaders, though financial ratios are not provided in the current dataset. A dividend of $0.17 is scheduled for payment on June 18, 2026.
Outlook is mixed; strong tech sector positioning supports growth potential, but high valuations and concentration risks warrant caution. Key catalysts include AI-driven earnings growth, while risks involve market volatility and stretched expectations. Investors should weigh entry points carefully amid current sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
